At a glance
- Originator Tanabe Seiyaku
- Class Antihyperlipidaemics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Hypercholesterolaemia
Most Recent Events
- 14 Aug 2001 Discontinued-II for Hypercholesterolaemia in Japan (Unknown route)
- 13 Nov 1998 No-Development-Reported for Hypercholesterolaemia in Japan (Unknown route)
- 17 Sep 1996 New profile